Dare Bioscience Inc
darebioscience.comWhat Do They Do?
Develops prescription medicines and consumer health products for women's health, serving women and healthcare providers.
10-K for FY2025, filed Mar 26, 2026We are a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world…View ↗
We regularly hear from healthcare providers, researchers, and women themselves about the urgent need for expanded access to evidenced-based…View ↗
In March 2025, we announced an expansion of our business model to include a dual-path approach to bringing new products to market. For…View ↗
Our business strategy is to in-license or otherwise acquire the rights to intellectual property and know-how that enables us to develop and…View ↗
How Do They Make Money?
For DARE to PLAY, prescription payment is due when the product is available for pharmacy dispensing. Under licensing agreements, Daré can also receive upfront fees, milestone payments and royalties on licensed-product sales.
10-K for FY2025, filed Mar 26, 2026The product currently is available for pre-fulfillment, which means that women may complete a telehealth consultation or in-person…View ↗
Collaboration Revenues. The Company enters into collaboration and licensing agreements under which it out-licenses certain rights to its…View ↗
License Fee Revenue. If the license to the Company’s intellectual property is determined to be distinct from the other performance…View ↗
Royalties. For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and for which the…View ↗
$1M
-
10-K for FY2025, filed Mar 26, 2026
$1M ↗
Who Are Their Customers?
Women buy consumer products directly through the DARE Health Hub; clinicians prescribe prescription products, which pharmacies dispense, with telehealth services supporting access.
8-K, filed Aug 13, 2026 10-K for FY2025, filed Mar 26, 2026Launched Flora Sync LF5 through the DARE Health Hub, establishing the Company’s first direct-to-consumer product offering.View ↗
Do Revenues Turn Into Profits?
No. It lost $13.4M in FY2025.
10-K for FY2025, filed Mar 26, 2026
−$13.6MView ↗
10-K for FY2025, filed Mar 26, 2026
−$13.4MView ↗
10-K for FY2025, filed Mar 26, 2026
−$10.3MView ↗
How Are They Changing?
-
Jul 17, 2026
Nasdaq warned Daré its stock could be delisted
Nasdaq said the stock was subject to delisting unless Daré requested a hearing; Daré said it intended to request one.
Sources
8-K, filed Jul 17, 2026
On July 13, 2026, Dare Biosciences, Inc. (the “Company”) was notified by the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock…View ↗
More routes to market
The older report described physician-prescribed candidates pursued through development and approval; the latest adds compounded prescription products and non-prescription consumer products as additional routes to market.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 26, 2026
Who Do They Compete With?
Competes with Astellas Pharma, Bayer, and Antiva Biosciences
10-K for FY2025, filed Mar 26, 2026If we are successful in bringing DARE to RECLAIM, or DARE-HRT1 to market, these products will compete with the many products on the market…View ↗
Loading...
